CN114982970B - 一种辅助保护内腔粘膜的营养素含片及其制备方法 - Google Patents
一种辅助保护内腔粘膜的营养素含片及其制备方法 Download PDFInfo
- Publication number
- CN114982970B CN114982970B CN202210428597.4A CN202210428597A CN114982970B CN 114982970 B CN114982970 B CN 114982970B CN 202210428597 A CN202210428597 A CN 202210428597A CN 114982970 B CN114982970 B CN 114982970B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- buccal tablet
- calculated
- nutrient
- selenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 109
- 239000006189 buccal tablet Substances 0.000 title claims abstract description 74
- 229940046011 buccal tablet Drugs 0.000 title claims abstract description 72
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 316
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 82
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 82
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 82
- 239000011718 vitamin C Substances 0.000 claims abstract description 82
- 239000011669 selenium Substances 0.000 claims abstract description 78
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 57
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 56
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 44
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 44
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940046009 vitamin E Drugs 0.000 claims abstract description 17
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 17
- 239000011709 vitamin E Substances 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 239000002211 L-ascorbic acid Substances 0.000 claims description 76
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 76
- 229960005070 ascorbic acid Drugs 0.000 claims description 76
- 238000002156 mixing Methods 0.000 claims description 55
- 239000003826 tablet Substances 0.000 claims description 55
- 239000000463 material Substances 0.000 claims description 46
- 239000002245 particle Substances 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 239000000230 xanthan gum Substances 0.000 claims description 29
- 229920001285 xanthan gum Polymers 0.000 claims description 29
- 229940082509 xanthan gum Drugs 0.000 claims description 29
- 235000010493 xanthan gum Nutrition 0.000 claims description 29
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 26
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 21
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 19
- 229960005055 sodium ascorbate Drugs 0.000 claims description 19
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 17
- 239000011755 sodium-L-ascorbate Substances 0.000 claims description 17
- 235000019187 sodium-L-ascorbate Nutrition 0.000 claims description 17
- 239000011692 calcium ascorbate Substances 0.000 claims description 16
- 229940047036 calcium ascorbate Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 15
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 15
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 229960002477 riboflavin Drugs 0.000 claims description 15
- 235000010356 sorbitol Nutrition 0.000 claims description 15
- 239000000600 sorbitol Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 229960002920 sorbitol Drugs 0.000 claims description 14
- 108010011485 Aspartame Proteins 0.000 claims description 13
- 239000004376 Sucralose Substances 0.000 claims description 13
- 235000010357 aspartame Nutrition 0.000 claims description 13
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 13
- 239000000605 aspartame Substances 0.000 claims description 13
- 229960003438 aspartame Drugs 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- 235000019192 riboflavin Nutrition 0.000 claims description 13
- 239000002151 riboflavin Substances 0.000 claims description 13
- 235000019408 sucralose Nutrition 0.000 claims description 13
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 13
- 229940011671 vitamin b6 Drugs 0.000 claims description 13
- 235000008160 pyridoxine Nutrition 0.000 claims description 11
- 239000011677 pyridoxine Substances 0.000 claims description 11
- 229960000984 tocofersolan Drugs 0.000 claims description 10
- 239000002076 α-tocopherol Substances 0.000 claims description 10
- 235000004835 α-tocopherol Nutrition 0.000 claims description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 10
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 9
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 9
- 240000002319 Citrus sinensis Species 0.000 claims description 9
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 9
- 239000002967 calcium-L-ascorbate Substances 0.000 claims description 9
- 235000005937 calcium-L-ascorbate Nutrition 0.000 claims description 9
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 8
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 7
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 7
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 7
- 235000004634 cranberry Nutrition 0.000 claims description 7
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- 244000131522 Citrus pyriformis Species 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 244000060011 Cocos nucifera Species 0.000 claims description 4
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 4
- 240000000560 Citrus x paradisi Species 0.000 claims description 3
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 claims description 3
- 240000000588 Hericium erinaceus Species 0.000 claims description 3
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 3
- 240000004153 Hibiscus sabdariffa Species 0.000 claims description 3
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 claims description 3
- 244000246386 Mentha pulegium Species 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 3
- 241000287420 Pyrus x nivalis Species 0.000 claims description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 235000012730 carminic acid Nutrition 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- 235000002864 food coloring agent Nutrition 0.000 claims description 3
- 239000009627 gardenia yellow Substances 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 2
- 241000335053 Beta vulgaris Species 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 claims description 2
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 2
- 235000019164 vitamin B2 Nutrition 0.000 claims 2
- 239000011716 vitamin B2 Substances 0.000 claims 2
- 235000019158 vitamin B6 Nutrition 0.000 claims 2
- 239000011726 vitamin B6 Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 31
- 235000019640 taste Nutrition 0.000 abstract description 24
- 206010061218 Inflammation Diseases 0.000 abstract description 21
- 230000004054 inflammatory process Effects 0.000 abstract description 21
- 206010039083 rhinitis Diseases 0.000 abstract description 16
- 201000007100 Pharyngitis Diseases 0.000 abstract description 15
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 abstract description 13
- 206010046914 Vaginal infection Diseases 0.000 abstract description 8
- 208000003265 stomatitis Diseases 0.000 abstract description 7
- 208000004232 Enteritis Diseases 0.000 abstract description 5
- 208000006374 Uterine Cervicitis Diseases 0.000 abstract description 5
- 206010008323 cervicitis Diseases 0.000 abstract description 5
- 208000004145 Endometritis Diseases 0.000 abstract description 4
- 208000007882 Gastritis Diseases 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 77
- 229940091258 selenium supplement Drugs 0.000 description 49
- 239000007937 lozenge Substances 0.000 description 33
- 238000012360 testing method Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 208000005577 Gastroenteritis Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000007873 sieving Methods 0.000 description 10
- 238000009835 boiling Methods 0.000 description 9
- 238000005520 cutting process Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000007779 soft material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 206010039101 Rhinorrhoea Diseases 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010028748 Nasal obstruction Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 208000036071 Rhinorrhea Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 208000012873 acute gastroenteritis Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- -1 oxygen free radical Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000032974 Gagging Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010065716 Pharyngeal inflammation Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/205—Heterocyclic compounds
- A23L27/2052—Heterocyclic compounds having oxygen or sulfur as the only hetero atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/205—Heterocyclic compounds
- A23L27/2054—Heterocyclic compounds having nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种辅助保护内腔粘膜的营养素含片和制备方法,属于营养素补充剂技术领域。本发明的营养素含片,包含如下营养素:硒、维生素C,任选的进一步包含维生素E、维生素B2和/或维生素B6。本发明的营养素含片,属于无糖型保健食品,富含硒和维生素C,具有口感好、依从性高、适宜人群广等优势,能够安全有效辅助保护内腔粘膜,可明显改善炎症的症状,减少炎症的反复,例如:鼻炎、口腔炎、咽炎、胃炎、肠炎、子宫内膜炎、宫颈炎、阴道炎等。
Description
技术领域
本发明属于营养补充剂技术领域,确切地说是一种辅助保护内腔粘膜的营养素制剂。
背景技术
人体常见的内腔粘膜炎症,自上而下,包括鼻炎、口炎、咽炎、胃炎、肠炎、子宫内膜炎、宫颈炎、阴道炎等,均为常见病、多发病。鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜炎症。口炎是发生在口腔黏膜上的感染性或非感染性炎症,感染性口炎是因为细菌或者病毒感染而发生的口炎。咽炎是各种咽部炎症的统称,是由细菌、病毒感染、环境等因素引起的咽部黏膜及黏膜下组织的急性或慢性炎症。幽门螺杆菌是慢性胃炎的主要病原菌,是消化性溃疡和胃黏膜相关淋巴组织淋巴瘤的重要致病因子,也可能是胃癌的协同因子。肠炎指小肠以及大肠内膜炎症,通常由细菌、病毒等微生物感染所致。子宫内膜炎是子宫内膜发生的炎症,一般由结核菌和病原菌感染所致,多见于月经期、流产及分娩后,感染后将会导致子宫不规则出血、不孕、流产、反复发作的盆腔痛以及性交困难等,严重者影响正常生活和工作,是育龄期女性常见的妇科疾病。宫颈炎也是妇科常见疾病之一,多见于育龄妇女,为宫颈受损伤和病原体侵袭而致。阴道炎是导致阴道症状如瘙痒、灼痛、刺激和分泌物异常的一组病症,与感染(细菌、念珠菌为主)、菌群失调、激素水平有关。目前,大多数炎症多采用抗生素治疗,存在一定的耐药性及副作用,且治愈慢,易反复。反复炎症是癌症的一大诱因,例如阴道炎和宫颈炎患者HPV的发病率高、肝炎患者肝癌发病率高、胃肠炎患者消化道肿瘤发病率高。它们严重影响着人们的正常生活和工作,使人心神不安,工作效率下降。因此,研制具有提高抵抗力,且安全、有效的辅助保护内腔粘膜的产品,可明显改善炎症的症状,减少炎症的反复,具有较好的社会意义。
硒是谷胱甘肽过氧化酶的组成成分,此酶的作用是催化还原型谷胱甘肽与过氧化物的氧化还原反应,所以可以发挥抗氧化作用,是重要的自由基清除剂。免疫细胞在杀伤有害细胞过程中会被病毒、细菌等释放的一些过氧化物伤害,而谷胱甘肽过氧化物酶就可以在杀伤室外消灭逸出的过氧化物,专司保护巨噬细胞自身之职,延长这些白细胞的寿命,提高机体的抗感染能力。
病毒是一类寄生性侵染分子,无细胞结构,依赖宿主细胞完成核酸的自我复制。大量研究结果表明,多种病毒的复制受到硒元素的影响。机体缺硒时,病毒基因组不稳定增加,对人体有致病作用的突变增加,复制速度加快,同时宿主细胞遭受氧自由基的胁迫,从而引发机体一系列不良生理生化反应。补硒有利于抑制病毒的复制和破坏,其原因不仅仅是通过提高机体免疫力来起到保护作用,更重要的是硒可以直接作用于病毒。
维生素C为人体免疫功能所必须的营养素,缺乏维生素C,会导致免疫力下降。维生素C的免疫增强效应与白细胞(特别是嗜中性白细胞)的功能密切相关。白细胞含有丰富的维生素C,其含量随摄入维生素C量的增多而增多。感染时白细胞内的维生素C含量急剧减少,为治疗疾病,应及时恢复白细胞中的维生素C含量,从而增强嗜中性白细胞的趋化性和变形能力,提高杀菌能力。例如,从白细胞中失去的维生素C越多,感冒的程度越严重。在感染期间,白细胞非常活跃地吸收经口服而摄入的维生素C。因此,感染期间及时补充维生素C有利于恢复白细胞功能,从而提高免疫力。
维生素C可分解组胺,使炎症反应减轻。维生素C能够显著下调血清中以及巨噬细胞分泌的炎症因子IL-6和TNF-α水平,同时上调抗炎因子IL-10的水平,维生素C能调节炎性因子产生以及抑制炎性介质浸润。另外,维生素C不仅能有效清除氧自由基,同时还可以起到抑制脂质过氧化、减轻炎症充血、提高细胞膜完整性以及促进炎症渗出的作用。
维生素E属于具有抗氧化作用的脂溶性维生素,与维生素C具有协同抗氧化作用,与硒在防止过氧化损害方面具有互补作用,共同保护细胞膜的质膜结构的完整性。维生素E不仅可以抗衰老、保护皮肤,还能增强卵巢功能、防止习惯性流产等。
维生素B2是体内黄酶类辅基的组成部分,当缺乏时可影响机体的生物氧化,使代谢发生障碍,其病变多表现为口、眼、外生殖器部位的炎症,如口角炎、唇炎、舌炎、眼结膜炎和阴囊炎等。维生素B2可提高机体对蛋白质的利用率,维护皮肤和细胞膜的完整性。维生素B2参与细胞的生长代谢,是肌体组织代谢和修复的必须营养素,还参与维生素B6的代谢。
维生素B6又称吡哆素,在红细胞内转化为磷酸吡哆醛,作为辅酶对蛋白质、碳水化合物、脂类的各种代谢功能起作用。妊娠及哺乳期、烧伤、长期慢性感染、发热、肠道疾病(乳糜泻、热带口炎性肠炎、局限性肠炎、持续腹泻)等情况时,需要增加维生素B6摄入量。
另外,维生素C通常指L-抗坏血酸,其为白色结晶体或结晶粉末,无臭,味酸,易溶于水。L-抗坏血酸钠为白色至微黄白色结晶性粉末或颗粒,无臭,味咸,易溶于水。L-抗坏血酸钙为白色或淡黄色结晶性粉末,无臭,味维苦,易溶于水。富硒酵母是迄今为止国内最高效、最安全、营养最均衡的补硒制剂,是以添加亚硒酸钠的营养物质为原料,经啤母发酵,将亚硒酸钠与酵母体内的蛋白质和多糖有机结合转化为生物硒,再经分离、干燥制得。富硒酵母为淡黄色至浅黄棕色颗粒或粉末,具有酵母的特殊气味。由于维生素C和富硒酵母的滋味和气味原因,目前大多市售维生素C含片或咀嚼片的产品中维生素C每片的含量较低;富硒酵母片一般为吞服片;更无大剂量维生素C和富硒酵母做成的无糖型的含片或咀嚼片产品。
发明内容
本发明的目的在于克服现有技术缺陷,提供一种口感好且无糖的高含量硒和维生素C的营养素含片及制备方法,能够安全有效的辅助保护内腔粘膜,可明显改善炎症的症状,减少炎症的反复。
本发明的具体技术方案如下:
一种辅助保护内腔粘膜的营养素含片,包含硒、维生素C,任选的,还包括其他组分,所述的其他组分选自维生素E、维生素B2、维生素B6中的一种或多种。
在一些实施例中,所述维生素C选自L-抗坏血酸、L-抗坏血酸钠和L-抗坏血酸钙中的一种或多种。
在一些实施例中,所述维生素C由L-抗坏血酸、L-抗坏血酸钠和L-抗坏血酸钙三种化合物组成,其中,L-抗坏血酸占维生素C(以L-抗坏血酸计)的22.5%~32.5%;L-抗坏血酸钠占维生素C(以L-抗坏血酸计)的50%~70%;L-抗坏血酸钙占维生素C(以L-抗坏血酸计)的7.5%~17.5%。优选的,L-抗坏血酸占维生素C(以L-抗坏血酸计)的25%~30%;L-抗坏血酸钠占维生素C(以L-抗坏血酸计)的55%~65%;L-抗坏血酸钙占维生素C(以L-抗坏血酸计)的10%~15%。更优选的,L-抗坏血酸占维生素C(以L-抗坏血酸计)的25%~30%;L-抗坏血酸钠占维生素C(以L-抗坏血酸计)的60%;L-抗坏血酸钙占维生素C(以L-抗坏血酸计)的10%~15%。更优选的,L-抗坏血酸占维生素C(以L-抗坏血酸计)的25%~28%;L-抗坏血酸钠占维生素C(以L-抗坏血酸计)的60%;L-抗坏血酸钙占维生素C(以L-抗坏血酸计)的12%~15%。
在一些实施例中,所述硒为富硒酵母(含量规格2000ppm)。
在一些实施例中,所述维生素E为dl-α-醋酸生育酚包埋粉(含量规格50%)。
在一些实施例中,所述维生素B2为核黄素。
在一些实施例中,所述维生素B6为盐酸吡哆醇。
在本发明的一个实施方案中,本发明的抗炎营养素含片中每片含有:硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)200~500mg。
优选的,抗炎营养素含片每片含有:硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)300~500mg。
优选的,抗炎营养素含片每片含有:硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)400~500mg。
进一步优选的,抗炎营养素含片每片含有:硒(以Se计)30~60μg、维生素C(以L-抗坏血酸计)450~500mg。
在本发明的一个实施方案中,任选的,所述的抗炎营养素含片每片还含有以下组分中的一种或多种:维生素E(以d-α-生育酚计)14~50mg、维生素B2(以核黄素计)1.4~10mg、维生素B6(以吡哆醇计)1.4~10mg。
在本发明的一些实施方案中,所述的抗炎营养素含片中包含硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)200~500mg、维生素E(以d-α-生育酚计)14~50mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)300~500mg、维生素E(以d-α-生育酚计)14~50mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)400~500mg、维生素E(以d-α-生育酚计)14~50mg;更优选硒(以Se计)30~60μg、维生素C(以L-抗坏血酸计)450~500mg、维生素E(以d-α-生育酚计)14~50mg。
在本发明的一些实施方案中,所述的抗炎营养素含片中包含硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)200~500mg、维生素B2(以核黄素计)1.4~10mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)300~500mg、维生素B2(以核黄素计)1.4~10mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)400~500mg、维生素B2(以核黄素计)1.4~10mg;更优选硒(以Se计)30~60μg、维生素C(以L-抗坏血酸计)450~500mg、维生素B2(以核黄素计)1.4~10mg。
在本发明的一些实施方案中,所述的抗炎营养素含片中包含硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)200~500mg、维生素B6(以吡哆醇计)1.4~10mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)300~500mg、维生素B6(以吡哆醇计)1.4~10mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)400~500mg、维生素B6(以吡哆醇计)1.4~10mg;更优选硒(以Se计)30~60μg、维生素C(以L-抗坏血酸计)450~500mg、维生素B6(以吡哆醇计)1.4~10mg。
本在本发明的一些实施方案中,所述的抗炎营养素含片中包含硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)200~500mg、维生素E(以d-α-生育酚计)14~50mg、维生素B2(以核黄素计)1.4~10mg、维生素B6(以吡哆醇计)1.4~10mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)300~500mg、维生素E(以d-α-生育酚计)14~50mg、维生素B2(以核黄素计)1.4~10mg、维生素B6(以吡哆醇计)1.4~10mg;优选硒(以Se计)30~90μg、维生素C(以L-抗坏血酸计)400~500mg、维生素E(以d-α-生育酚计)14~50mg、维生素B2(以核黄素计)1.4~10mg、维生素B6(以吡哆醇计)1.4~10mg;更优选硒(以Se计)30~60μg、维生素C(以L-抗坏血酸计)450~500mg、维生素E(以d-α-生育酚计)14~50mg、维生素B2(以核黄素计)1.4~10mg、维生素B6(以吡哆醇计)1.4~10mg。
本发明的抗炎营养素含片,任选地,还包括食品可接受的辅料。
进一步的,本发明的抗炎营养素含量,每片片重为1.0g-1.5g,优选1.2g。
所述辅料选自山梨糖醇、黄原胶、硬脂酸镁、阿斯巴甜、三氯蔗糖、果蔬粉、食用色素和食用香精中的一种或多种。
在一些实施例中,所述黄原胶的粘度(1%黄原胶在1%KCl水溶液中)为1200-1800cps,优选1500cps。在一些实施例中,每片营养素含片中黄原胶的用量为12mg-18mg,优选13mg-16mg,更优选15mg。
在一些实施例中,每片营养素含片中山梨糖醇的用量为400mg-850mg;优选500-620mg。
在一些实施例中,每片营养素含片中硬脂酸镁的用量为0-20mg,优选10mg-20mg。
在一些实施例中,每片营养素含片中阿斯巴甜的用量为0-5mg,优选1mg-5mg。
在一些实施例中,每片营养素含片中三氯蔗糖的用量为0-5mg,优选0.5mg-5mg。
在一些实施例中,所述果蔬粉选自甜橙粉、蔓越莓粉、猴头菇粉、雪梨粉中的一种或几种;每片营养素含片中果蔬粉的用量为1mg-100mg,优选20-60mg。
在一些实施例中,所述食用色素选自栀子黄、红花黄、姜黄素、柠檬黄及其铝色淀、萝卜红、玫瑰茄红、葡萄皮红、甜菜红、胭脂红及其铝色淀中的一种或几种;每片营养素含片中食用色素的用量为0mg-10mg,优选0.1mg-1mg。
在一些实施例中,所述食用香精选自甜橙香精、西柚香精、蓝莓香精、椰子香精、蔓越莓香精、薄荷香精中的一种或几种;每片营养素含片中食用香精的用量为0mg-20mg,优选1mg-10mg。
本发明采用限定每片营养素中各组分的含量得到的抗炎营养素的含片,本领域技术人员根据实际需求,按照本发明的精神及同比例的扩大或缩小的原则制备得到的不同片重的抗炎营养素含片,均在本发明的范围内。
另一方面,本发明还提供所述抗炎营养素含片的制备方法,包括如下步骤:将硒、维生素C,任选的其他组分和/或辅料混合均匀,压片,即得。
在一些实施例中,本发明的抗炎营养素含片的制备方法,包括如下步骤:
(1)将硒、L-抗坏血酸钠、L-抗坏血酸钙与山梨糖醇、黄原胶、任选的果蔬粉,加入到湿法制粒机制粒、干燥,得到干颗粒;
(2)将L-抗坏血酸、任选的其他组分、任选的食用香精、硬脂酸镁混合均匀,得外加物料;
(3)将步骤(1)所得干颗粒与步骤(2)所得外加物料,混合均匀,得总混物料;
(4)将总混物料压片,得抗炎营养素含片。
在一些实施例中,本发明的抗炎营养素含片的制备方法,包括如下步骤:
(1)将L-抗坏血酸钠,粉碎,备用。
(2)将硒、L-抗坏血酸钠、L-抗坏血酸钙与山梨糖醇、黄原胶、任选的果蔬粉,加入到湿法混合制粒机中,制粒,干燥,过筛,得干颗粒;
(3)将维生素B2、维生素B6与任选的食用色素、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、维生素E、任选的食用香精、硬脂酸镁混合均匀,得外加物料;
(4)将步骤(2)所得干颗粒与步骤(3)所得外加物料,混合均匀,得总混物料;
(5)将总混物料,通过旋转式压片机压片,控制片重,得抗炎营养素含片。
本发明的有益效果是:
1.本发明的抗炎营养素含片富含高含量的硒和维生素C,具有较好的稳定性,具有显著提高机体免疫力的功效。针对内腔粘膜炎症(例如:鼻炎、口腔炎、咽炎、胃炎、肠炎、子宫内膜炎、宫颈炎、阴道炎等)患者补充特定的营养素,能够起到安全有效辅助保护内腔粘膜的作用,可明显改善炎症的症状,减少炎症的反复。研究显示,本发明提供的营养素含片,①对于鼻炎患者在流鼻涕、打喷嚏、鼻塞等症状减轻和次数减少方面,服用4周的有效率为81%;②具有改善抗妇科炎症的辅助作用;③可明显减轻慢性咽炎患者症状,总有效率为80%;④对于急性胃肠炎患者在腹泻、恶心、呕吐及发热等临床症状改善减轻或次数减少方面,服用2周的有效率为85%。
2.本发明制备的营养素含片,属于无糖型保健食品,将酸(L-抗坏血酸)、甜、苦(L-抗坏血酸钙、维生素B2)、咸(L-抗坏血酸钠)、香充分柔和在一起,具有“口感好且无糖”的特点,适应现代人的接受习惯,依从性高,适宜人群广。安全无毒副作用,适合长期每日服用。
3.本发明的营养素含片的制备方法简单,易于实现工业化生产,经济环保。
4.本发明通过大量研究发现,采用三种不同的维生素C组分制备营养素含片,维生素C含量最高可达500mg/片,不仅掩盖了富硒酵母的特殊气味,且酸度适中,口感好。同时,发明人意外的发现,制备工艺中外加L-抗坏血酸,不参与制粒工艺,可以更好的起到酸度调节剂的作用,进一步调节含片的口感。
5.本项目的研发过程中还针对辅料对含片口感的影响进行了研究。通过大量的试验发现,黄原胶对含片的口感影响较大,当黄原胶含量为15mg时,制备得到的含量口感更优。
附图说明
图1:筛选维生素C来源及占比口感测试评分,满分为10分。
图2:产品可接受程度投票人数占比,单位:%。
图3:抗鼻炎临床有效率,单位:%。
图4:抗胃肠炎临床有效率,单位:%。
图5:筛选黄原胶用量口感测试评分,满分为10分。
具体实施方式
本发明公开了一种辅助保护内腔粘膜的营养素含片和制备方法,本领域技术人员可以借鉴本发明的内容,结合营养制剂和食用原辅料的相关原理,适当改进原辅料和工艺参数来实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明范围内。
为了更好地理解本发明而不是限制本发明的范围,在本申请中所用的表示用量、百分比的所有数字、以及其他数值,在所有情况下都应理解为以词语“大约”所修饰。各个数字参数至少应被看作是根据所报告的有效数字和通过常规的四舍五入方法而获得的。
其中所述的方式,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均为食品级或医药级,均可以从商业途径获得。
在下文的描述中,给出了大量具体的细节以便提供对本发明更为彻底的理解。然而,对于本领域技术人员而言显而易见的是,本发明可以无需一个或多个这些细节而得以实施。为了避免与本发明发生混淆,对于本领域公知的一些技术特征未进行描述。
黄原胶:规格为9720,粘度(1%黄原胶在1%KCl水溶液中)为1500cps,粒度为95%以上通过80目筛,来源于鄂尔多斯市中轩生化股份有限公司。
实施例1:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、黄原胶,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量80%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将柠檬黄铝色淀、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、甜橙香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
实施例2:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
实施例3:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
实施例4:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
实施例5:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
实施例6:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
实施例7:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
对比例1:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、山梨糖醇、黄原胶,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量80%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将柠檬黄铝色淀、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、甜橙香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
对比例2:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
对比例3:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例1。
对比例4:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、黄原胶,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量80%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将柠檬黄铝色淀、三氯蔗糖、阿斯巴甜混合均匀,再与甜橙香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
实施例8:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、黄原胶、甜橙粉,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量80%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将柠檬黄铝色淀、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、西柚香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
实施例9:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、黄原胶、蔓越莓粉,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量85%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将胭脂红铝色淀、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、dl-α-醋酸生育酚包埋粉、蓝莓香精、椰子香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
实施例10:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、黄原胶、蔓越莓粉,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量85%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将玫瑰茄红、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、dl-α-醋酸生育酚包埋粉、蔓越莓香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
实施例11:抗炎营养素含片
(1)配方组成:
/>
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、黄原胶、雪梨粉,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量90%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将核黄素与栀子黄、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、薄荷香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
实施例12:抗炎营养素含片
(1)配方组成:
/>
(2)制备方法:同实施例11。
实施例13:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、低聚果糖、黄原胶、猴头菇粉,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量90%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将盐酸吡哆醇与姜黄素、三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、椰子香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
实施例14:抗炎营养素含片
(1)配方组成:
(2)制备方法:
A.将L-抗坏血酸钠,经80目粉碎,备用。
B.将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙、山梨糖醇、黄原胶,加入到湿法混合制粒机中,搅拌80转/min、切碎1200转/min,混合3min,制软材2min,缓慢加入适量90%的酒精溶液,制得湿颗粒;将湿颗粒于40℃~50℃沸腾干燥至水分≤1%,过30目筛,得干颗粒;
C.将核黄素、盐酸吡哆醇与三氯蔗糖、阿斯巴甜混合均匀,再与L-抗坏血酸、dl-α-醋酸生育酚包埋粉、甜橙香精、硬脂酸镁混合均匀,得外加物料;
D.将所得干颗粒与所得外加物料,混合均匀,得总混物料;
E.将总混物料,通过旋转式压片机压片,控制片重1.2g/片,得抗炎营养素含片。
对比例5:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例14。
对比例6:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例14。
对比例7:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例14。
对比例8:抗炎营养素含片
(1)配方组成:
(2)制备方法:同实施例14。
实施例15:口感测评筛选维生素C来源及占比
筛选10人(男女各5人)对实施例1-7、对比例1-4所得产品进行口感测评,以满分为10分,得分越高,口味越好为评价标准:3分及以下,口含难接受;4-6分,口含可接受;7-10分,口含易接受。结果显示:实施例6口感最佳,测试结果如图1所示。
由图1可知:当L-抗坏血酸占维生素C(以L-抗坏血酸计)的22.5%~32.5%;L-抗坏血酸钠占维生素C(以L-抗坏血酸计)的50%~70%;L-抗坏血酸钙占维生素C(以L-抗坏血酸计)的7.5%~17.5%时,如实施例1-7,制备得到的抗炎营养素含片的口感评分在4分以上,尤其是当L-抗坏血酸占维生素C(以L-抗坏血酸计)的25%~30%;L-抗坏血酸钠占维生素C(以L-抗坏血酸计)的60%;L-抗坏血酸钙占维生素C(以L-抗坏血酸计)的10%~15%时,如实施例5-7,制备得到的抗炎营养素含片的口感评分在7分以上;而当L-抗坏血酸占维生素C(以L-抗坏血酸计)比例低于22.5%或高于32.5%,L-抗坏血酸钠占维生素C(以L-抗坏血酸计)的60%;L-抗坏血酸钙占维生素C(以L-抗坏血酸计)比例低于7.5%或高于17.5%时,如对比例1-3,制备得到的抗炎营养素含片的口感评分在3分以下,口感较差。
对比分析实施例6和对比例4,配方组成相同,区别在于L-抗坏血酸加入方式不同,实施例6的制备工艺中,采用外加L-抗坏血酸,即L-抗坏血酸不进行制粒,制备得到的抗炎营养素含片的口感评分为9.5分,对比例4的制备工艺中,采用内加L-抗坏血酸,即对L-抗坏血酸进行制粒,制备得到的抗炎营养素含片的口感评分为6.7分,口感评分相差2.8分,因此制备工艺中,优选采用外加L-抗坏血酸。
实施例16:口感测评产品可接受程度
筛选20人(男女各10人)分别对实施例8-14所得产品进行口感测评,以酸、咸、苦、适中四种情况为评价标准,满分为20分,进行投票,评定产品可接受程度和改进方向。结果显示:实施例8-14的可接受度不低于60%,测试结果如表1及图2所示。
表1产品可接受程度口感测评结果
实施例17:抗鼻炎临床研究
(1)实验目的:抗鼻炎功效评价。
(2)试验样品:实施例6制得的抗炎营养素含片(批次:3681211001)。
(3)试验人群:鼻炎患者60人,男女各半,年龄30~50岁。
表2抗炎营养素含片(鼻炎)试验人群
(4)试验方法:不改变原来的生活习惯,正常饮食和工作,期间不得服用其他消炎类产品。每日早饭后,含服1片样品,连续服用4周。以流鼻涕、打喷嚏、鼻塞等主要症状改善情况为评价指标,分别在服用样品1周、2周、4周后,采用自身前后对照方法进行比较。
(5)判定标准:
有效:流鼻涕、打喷嚏、鼻塞等症状明显改善或完全消失;
无效:流鼻涕、打喷嚏、鼻塞等症状无显著改善,且鼻涕增多,疼痛症状增加;或有所改善,但仍伴有1~2种症状。
不好判断:不能判断为有效或无效。
(6)试验结果:本发明的抗炎营养素含片(鼻炎),对于鼻炎患者在流鼻涕、打喷嚏、鼻塞等症状减轻或次数减少方面,服用1周的有效率为14%;服用2周的有效率为65%;服用4周的有效率为81%,并对伴随症状(头疼、咽干咽痛)有改善作用,未发现与试食样品有关的不良反应。证明,本发明的抗炎营养素含片(鼻炎)具有抗鼻炎的功能,且无副作用。
抗鼻炎评价结果如表3及图3所示。
表3抗炎营养素含片(鼻炎)临床试验结果
实施例18:抗妇科炎症临床研究
(1)实验目的:抗妇科炎症疗效评价。
(2)试验样品:实施例9制得的抗炎营养素含片(批次:3681211002);甲硝唑片(远大医药,国药准字H42021947,0.2g/片)。
(3)试验人群:细菌性阴道炎患者(诊断标准:a.阴道分泌物pH值>4.5;b.白带增多,匀质稀薄;c.胺臭味试验结果阳性;d.线索细胞试验结果阳性)120人,按照年龄、病程等一般资料,随机分为对照组与观察组。
表4抗炎营养素含片(阴道炎)试验人群
组别 | 招募例数 | 脱落例数 | 脱落率 | 统计例数 | 平均年龄 | 平均病程 |
对照组 | 60 | 3 | 5% | 57 | 41.23±8.02岁 | 3.35±1.07年 |
观察组 | 60 | 3 | 5% | 57 | 40.95±7.96岁 | 3.22±1.23年 |
(4)试验方法:对照组患者口服甲硝唑片(0.4g/次,2次/d),观察组在对照组基础上给予本发明实施例9制得的样品,含服1片/d,连续服用1周。
(5)疗效判定标准:
治愈:患者临床症状消失,诊断标准中4项检测均为阴性;
显效:患者临床症状明显改善,诊断标准4项检测中3项为阴性;
有效:患者临床症状有所改善,诊断标准4项检测中有2项为阴性;
无效:患者临床症状未改善或出现恶化,诊断标准4项检测中有1项为阴性或均未转为阴性。
总有效率为治愈、显效和有效的总和。
(6)试验结果:观察组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。证明,本发明的抗炎营养素含片(阴道炎)具有抗妇科炎症的辅助治疗作用,且无副作用。
临床疗效结果如表5所示。
表5抗炎营养素含片(阴道炎)临床疗效结果
实施例19:抗咽炎临床研究
(1)实验目的:抗咽炎功效评价。
(2)试验样品:实施例11制得的抗炎营养素含片(批次:3681211003)。
(3)试验人群:慢性咽炎患者50人,男女各半,年龄40~60岁。
表6抗炎营养素含片(咽炎)试验人群
(4)试验方法:不改变原来的生活习惯,正常饮食和工作,期间不得服用其他消炎类产品。每日2次,每次含服1片样品,连续服用2周。以咽部不通、发痒、灼热、干燥、微痛、异物感或堵塞感、咽分泌物增多、咽反射敏感和刺激性咳嗽等9个主要症状均分为轻(1-5分)、中(6-10分)、重3级(11-15分),每级5分。(治疗前症状总分-治疗后症状总分)/治疗前症状总分×100%,即是临床症状减少的百分比,亦谓疗效指数,据此来判定疗效。
(5)疗效判定标准:
治愈:治疗后症状总分是0;
显效:疗效指数在76%以上;
有效:疗效指数在51%~75%之间;
好转:疗效指数在26%~50%之间;
无效:疗效指数在25%以下。
总有效率为治愈、显效和有效的总和。
(6)不良反应评定:
本试验考察的不良反应有胃肠道不适、瘙痒、皮疹、水肿、发热等。0为无不适;1为轻度不适,未明显影响日常生活;2为中度不适,并影响日常活动;3为重度不适,明显影响日常活动,需卧床休息。
(7)试验结果:本发明的抗炎营养素含片(咽炎),可明显减轻慢性咽炎患者症状,总有效率为80%,未发现与试食样品有关的不良反应。证明,本发明的抗炎营养素含片(咽炎)具有抗咽炎的功能,且无副作用。
评价结果如表7所示。
表7抗炎营养素含片(咽炎)临床试验结果
实施例20:抗胃肠炎临床研究
(1)实验目的:抗胃肠炎功效评价。
(2)试验样品:实施例13制得的抗炎营养素含片(批次:3681211004)。
(3)试验人群:急性胃肠炎患者,且伴有不同程度的恶心、呕吐、腹泻、发热及腹痛等症状。50人,男女各半,年龄30~50岁。
表8抗炎营养素含片(胃肠炎)试验人群
(4)试验方法:所有患者给予常规治疗,包括补充水电解质、调节酸碱平衡、营养支持及抗感染治疗等。期间确保清淡饮食,严禁烟酒及刺激性食物,停用其他药物。每日1次,每次含服1片样品,连续服用2周。以腹泻、恶心、呕吐及发热等临床症状改善情况为评价指标,分别在服用样品1周、2周后,采用自身前后对照方法进行比较。
(5)判定标准:
显效:治疗后,患者的临床症状和体征显著消失,经检查,均恢复至正常状态;
有效:患者的临床症状、体征明显缓解,经检查,明显好转;
无效:经治疗后,患者的临床症状无变化甚至加重,经检查恶化或者未好转。
(6)试验结果:本发明的抗炎营养素含片(胃肠炎),对于急性胃肠炎患者在腹泻、恶心、呕吐及发热等临床症状改善减轻或次数减少方面,服用1周的有效率为69%;服用2周的有效率为85%,未发现与试食样品有关的不良反应。证明,本发明的抗炎营养素含片(胃肠炎)具有抗胃肠炎的功能,且无副作用。
抗胃肠炎评价结果如表9及图4所示。
表9抗炎营养素含片(胃肠炎)临床试验结果
实施例21:口感测评筛选黄原胶用量
筛选10人(男女各5人)对实施例8-14、对比例5-8所得产品进行口感测评,以满分为10分,得分越高,口味越好为评价标准:3分及以下,口含难接受;4-6分,口含可接受;7-10分,口含易接受。结果显示(如图5所示):黄原胶对产品口味的影响较明显,与其大分子特殊结构和胶体特定有关,其极强的吸水性,与唾液接触会快速成胶团,可减少对味蕾的刺激,起到柔和味道使得口感爽滑的作用。当黄原胶用量较低时,如对比例5、对比例6、对比例7所示,起不到改善口感的作用;当黄原胶用量过高(例如对比例8),过多的黄原胶使得含片的粘度过高,有糊嘴的感觉,影响口感。
Claims (8)
1.一种辅助保护内腔粘膜的营养素含片,包含硒、维生素C;所述硒为富硒酵母;所述的维生素C由L-抗坏血酸、L-抗坏血酸钠和L-抗坏血酸钙三种化合物组成;每片片重为1.0g-1.5g,以富硒酵母和维生素C为主要有效成分;每片营养素含片含量为:硒以Se计30~90μg、维生素C以L-抗坏血酸计450~500mg;L-抗坏血酸占维生素C的25%~30%;L-抗坏血酸钠占维生素C的55%~65%;L-抗坏血酸钙占维生素C的10%~15%,所述维生素C、L-抗坏血酸、L-抗坏血酸钠、L-抗坏血酸钙的量均以L-抗坏血酸计;还包含食品可接受的辅料;所述辅料有黄原胶;每片营养素含片含黄原胶12-18mg。
2.如权利要求1所述的营养素含片,其特征在于,还包括其他组分,所述的其他组分选自维生素E、维生素B2、维生素B6中的一种或多种,其中维生素E以d-α-生育酚计14~50mg、维生素B2以核黄素计1.4~10mg、维生素B6以吡哆醇计1.4~10mg。
3.如权利要求1所述的营养素含片,其特征在于,每片营养素含片含黄原胶15mg。
4.如权利要求1所述的营养素含片,其特征在于,所述辅料还选自山梨糖醇、硬脂酸镁、阿斯巴甜、三氯蔗糖、果蔬粉、食用色素和食用香精中的一种或几种。
5.如权利要求4所述的营养素含片,其特征在于,所述果蔬粉选自甜橙粉、蔓越莓粉、猴头菇粉、雪梨粉中的一种或几种。
6.如权利要求4所述的营养素含片,其特征在于:所述食用色素选自栀子黄、红花黄、姜黄素、柠檬黄及其铝色淀、萝卜红、玫瑰茄红、葡萄皮红、甜菜红、胭脂红及其铝色淀中的一种或几种。
7.如权利要求4所述的营养素含片,其特征在于:所述食用香精选自甜橙香精、西柚香精、蓝莓香精、椰子香精、蔓越莓香精、薄荷香精中的一种或几种。
8.如权利要求1至7中任一项所述的营养素含片的制备方法,其特征在于,包括如下步骤:将硒、维生素C,任选的其他组分和/或辅料混合均匀,压片,得到营养素含片;具体为:步骤1)将富硒酵母、L-抗坏血酸钠、L-抗坏血酸钙与山梨糖醇、黄原胶、任选的果蔬粉,加入到湿法制粒机制粒、干燥,得到干颗粒;
步骤2)将L-抗坏血酸、任选的其他组分、任选的食用香精、硬脂酸镁混合均匀,得外加物料;
步骤3)将步骤1)所得干颗粒与步骤2)所得外加物料,混合均匀,得总混物料;
步骤4)将总混物料压片,得营养素含片。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210112683 | 2022-01-29 | ||
CN2022101126834 | 2022-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114982970A CN114982970A (zh) | 2022-09-02 |
CN114982970B true CN114982970B (zh) | 2024-02-09 |
Family
ID=83024979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210428597.4A Active CN114982970B (zh) | 2022-01-29 | 2022-04-22 | 一种辅助保护内腔粘膜的营养素含片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114982970B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106165893A (zh) * | 2016-08-19 | 2016-11-30 | 江西中天医药生物有限公司 | 一种补充人体铬、硒和维生素c的保健食品 |
CN109123683A (zh) * | 2018-09-20 | 2019-01-04 | 济源市万洋冶炼(集团)有限公司 | 一种补充硒、维生素c的保健食品及其制备方法 |
WO2019106626A1 (en) * | 2017-12-01 | 2019-06-06 | Lewandowska Agata | Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis |
CN110226741A (zh) * | 2019-06-20 | 2019-09-13 | 上海奥医生物医药科技有限公司 | 一种溃疡性结肠炎专用型临床营养配方及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6859570B2 (ja) * | 2015-01-15 | 2021-04-14 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | ヒト機能性食品用の25−ヒドロキシビタミンdおよび酸化防止剤/抗炎症剤の組み合わせ |
-
2022
- 2022-04-22 CN CN202210428597.4A patent/CN114982970B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106165893A (zh) * | 2016-08-19 | 2016-11-30 | 江西中天医药生物有限公司 | 一种补充人体铬、硒和维生素c的保健食品 |
WO2019106626A1 (en) * | 2017-12-01 | 2019-06-06 | Lewandowska Agata | Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis |
CN109123683A (zh) * | 2018-09-20 | 2019-01-04 | 济源市万洋冶炼(集团)有限公司 | 一种补充硒、维生素c的保健食品及其制备方法 |
CN110226741A (zh) * | 2019-06-20 | 2019-09-13 | 上海奥医生物医药科技有限公司 | 一种溃疡性结肠炎专用型临床营养配方及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114982970A (zh) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008034316A1 (fr) | Préparation de composés capable de reduction rapide de stress oxidatif et son procédé de préparation | |
CN103550274B (zh) | 一种口腔用药制剂 | |
CN114982970B (zh) | 一种辅助保护内腔粘膜的营养素含片及其制备方法 | |
CN105213353B (zh) | 含有薁磺酸钠的复方口腔膜剂及制备方法 | |
Sareen et al. | Wheat grass-a wonder herb | |
CN105832993B (zh) | 一种具有清咽功能的组合物及其制备方法和应用 | |
KR100907670B1 (ko) | 가공된 땅콩 종피를 포함하는 알레르기성 질환의 치료 또는 예방제 | |
WO2002017944A1 (en) | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders | |
CN106138254A (zh) | 一种牛黄解毒口含片的制备方法及其应用 | |
CN109568428B (zh) | 小儿涌泉贴膏 | |
CN111973636A (zh) | 一种肛肠凝胶及其制备方法 | |
CN110051723A (zh) | 一种沙棘果口腔喷雾及其制备方法 | |
CN113425713B (zh) | 一种治疗十二指肠溃疡的药物组合物 | |
CN117562962B (zh) | 美洲大蠊或其提取物的用途及一种治疗猫口炎的中兽药组合物 | |
CN115337359B (zh) | 一种治疗螨虫皮炎的外用中药组合物及其制备方法 | |
CN113575958B (zh) | 提高免疫力功能的保健组合物、胶囊及制备方法 | |
CN112494598B (zh) | 一种用于治疗咽炎的有效部位组合物及其应用 | |
KR102498401B1 (ko) | 백내장 치료 및 예방용 안약 조성물 | |
CN112516158B (zh) | 一种用于治疗咽炎的组合物及其制备方法 | |
KR20190012943A (ko) | 구강작열감 증후군과 구내염 치료 및 예방용 조성물 | |
WO2021187635A1 (ko) | 호흡기 감염 질환 및 폐렴 감염 바이러스 예방 및 치료를 위한 혼합물 제조 | |
CN113018358A (zh) | 一种口腔修复液及其制备方法 | |
TW202408560A (zh) | 一種組合物用於治療眼睛疾病之醫藥品用途 | |
CN116115681A (zh) | 一种用于制备治疗扁桃体发炎药物的配方及方法 | |
CN114939149A (zh) | 一种清咽缓解体力疲劳组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |